From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example Publication From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example A case example is presented in which the physiologically based modeling approach has been used…CertaraMarch 1, 2012
Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs? Publication Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs? In 2005, a survey compared a number of commercial PBPK software available at the time,…CertaraMarch 1, 2012
Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events Publication Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events Positive allosteric modulators ('potentiators') of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) have been shown to display…CertaraMarch 1, 2012
Physiologically-based Pharmacokinetic Model for Topotecan in Mice Publication Physiologically-based Pharmacokinetic Model for Topotecan in Mice Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer.…CertaraFebruary 1, 2011
Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science Publication Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of age in drug development and…CertaraFebruary 1, 2011
PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals Publication PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals Generic PBPK models, applicable to a large number of substances, coupled to parameter databases and…CertaraDecember 30, 2010
Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam Publication Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam The aim of this study was to predict the magnitude of metabolic drug-drug interaction (mDDI)…CertaraMarch 18, 2010
Physiologically-based Pharmacokinetics (PBPK) Publication Physiologically-based Pharmacokinetics (PBPK) Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical species, and many…CertaraJune 1, 2009
Pharmacokinetic Predictions in Children by Using the Physiologically-based Pharmacokinetic Modeling Publication Pharmacokinetic Predictions in Children by Using the Physiologically-based Pharmacokinetic Modeling Nowadays, 50-90% of drugs used in children have never been actually studied in this population. Consequently, either…CertaraDecember 1, 2008
The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-based Simulation (Simcyp) Predicts In Vivo Metabolic Inhibition Publication The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-based Simulation (Simcyp) Predicts In Vivo Metabolic Inhibition BACKGROUND: Erlotinib is an orally active antitumor agent. Analyses in vitro using human liver microsomes and…CertaraJanuary 1, 2008